GRI Bio filings document a clinical-stage biotechnology issuer developing Natural Killer T cell modulators and the public-company events tied to that business. The filings include 8-K disclosures covering GRI-0621 clinical trial updates in idiopathic pulmonary fibrosis, financial-result releases and press-release exhibits furnished under results of operations and other-events items.
The filing record also details capital structure and governance matters, including at-the-market common stock offering agreements and prospectus supplements, legal opinions for share issuance, certificate amendments for a reverse stock split, Nasdaq Capital Market compliance notices, special meeting voting results and adjustments affecting common stock, warrants, convertible securities and equity incentive plans.
GRI Bio, Inc. reported that stockholders approved a reverse stock split authorization at a Special Meeting. The board may implement a split of the common stock at any ratio between one-for-two and one-for-thirty, without changing the number of authorized shares, and may also decide not to proceed even though the authority was granted. Stockholders also approved a proposal allowing postponement or adjournment of the meeting to gather more proxies if needed.
The company disclosed that it previously received a Nasdaq notice on November 26, 2025 for not meeting the minimum stockholders’ equity requirement of $2,500,000. On December 12, 2025 it completed a best efforts public offering of 2,603,331 shares of common stock, 8,063,336 pre-funded warrants, and 10,666,667 Series F warrants, generating gross cash proceeds of about $8.0 million. As a result, the company believes its stockholders’ equity now exceeds the Nasdaq minimum, though Nasdaq will continue to monitor compliance and could still delist the stock if future reports do not show sufficient equity.
GRI Bio, Inc. disclosed that it has increased the maximum amount of common stock that may be issued under its at-the-market offering program with H.C. Wainwright & Co., LLC to up to $7,379,813 of shares. The company notes this figure is in addition to approximately $6,165,114 of shares that have already been sold under the existing sales agreement. Certain provisions of a Securities Purchase Agreement dated December 11, 2025 were waived to permit issuances under this at-the-market arrangement, and a legal opinion from Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. regarding the validity of the shares was filed as an exhibit.
GRI Bio, Inc. is updating its at-the-market equity program to offer and sell up to $7,379,813 of common stock from time to time through H.C. Wainwright & Co. as sales agent under an existing sales agreement. This supplements earlier prospectus supplements and adjusts the amount the company may sell while remaining within the one-third public float limit set by General Instruction I.B.6 of Form S-3. The company notes that approximately $6,165,114 of common stock has already been sold under prior supplements, and that its public float was about $29.8 million based on 13,935,394 shares outstanding as of January 8, 2026. The common stock trades on the Nasdaq Capital Market under the symbol GRI, with a last reported sale price of $0.284 per share on January 8, 2026.
GRI Bio, Inc. reported that it has issued a press release sharing additional data from its Phase 2a clinical trial of GRI-0621 in patients with idiopathic pulmonary fibrosis, a serious lung disease. The filing does not describe the details or outcomes of the new data, only that they were announced.
The company also noted that, following a public offering completed in December 2025, it believes its stockholders’ equity is now above the minimum $2.5 million requirement set by Nasdaq. This suggests the company currently expects to meet the exchange’s stockholders’ equity standard for continued listing.
GRI Bio, Inc. reported that it issued a press release announcing the closing of a best efforts public offering of its common stock, pre-funded warrants to purchase common stock and Series F warrants to purchase common stock.
Immediately following completion of this offering, the company states that its stockholders’ equity exceeds $2.5 million, meaning its net assets are above this level after the transaction.
GRI Bio, Inc. is conducting a public offering of 2,603,331 shares of common stock and 8,063,336 pre-funded warrants, each paired with a Series F warrant, plus 746,667 placement agent warrants. Each share of common stock is sold with a Series F warrant at a combined price of $0.75, while each pre-funded warrant and accompanying Series F warrant is priced at $0.7499, for total gross proceeds of $8,000,000 and estimated net proceeds of about $6.7 million.
The company will use the cash for working capital, product development and general corporate purposes, while accepting dilution that could increase common shares outstanding from 3,268,727 to 13,935,394 before any warrant exercises. GRI Bio remains a clinical-stage biotech focused on its lead IPF candidate GRI-0621, but has a history of net losses, a going concern warning, and a Nasdaq stockholders’ equity deficiency notice, so it anticipates needing substantial additional capital beyond this raise.
GRI Bio, Inc. commenced a best efforts public offering of 2,603,331 shares of common stock, 8,063,336 pre-funded warrants and 10,666,667 Series F warrants, with each share or pre-funded warrant sold together with one Series F warrant. The combined price is $0.75 per share and Series F warrant, and $0.7499 per pre-funded warrant and Series F warrant. The company expects approximately $6.7 million in net proceeds.
GRI Bio plans to use the cash for working capital, product candidate development and general corporate purposes, and believes this funding, together with existing cash and cash equivalents, will support planned operations into the fourth quarter of 2026. The pre-funded warrants are exercisable at $0.0001 per share until fully exercised, while the Series F warrants are exercisable at $0.75 per share and expire on December 12, 2030, subject to 4.99% or 9.99% beneficial ownership limits and customary offering and financing restrictions.
GRI Bio, Inc., a Delaware-based biotechnology company headquartered in La Jolla, California, filed Amendment No. 1 to its Form S-1 registration statement. This amendment is described as an exhibits-only filing, meaning it primarily updates and compiles legal and contractual documents without changing the main disclosure sections. The exhibit list includes various forms of common stock purchase warrants, pre-funded warrants, Series F warrants, a form of securities purchase agreement, an updated engagement letter with H.C. Wainwright & Co., an equity incentive plan and related award agreements, key employment and consulting agreements, consents, and the filing fee table. The amendment is signed on behalf of the company by President and Chief Executive Officer W. Marc Hertz, Ph.D., and other directors and officers.
GRI Bio is offering 5,450,774 shares of common stock issuable upon exercise of its Series E-1, Series E-2, Series E-3, pre-funded and placement agent warrants under a prospectus supplement, following completion of a reasonable best efforts offering of 202,000 common shares and the related warrants.
The company also reports topline data from its Phase 2a GRI-0621-IPF-02 trial in idiopathic pulmonary fibrosis, where oral GRI-0621 met the primary endpoint of safety and tolerability over 12 weeks, showed placebo-adjusted improvements in forced vital capacity and favorable collagen biomarker shifts suggestive of anti-fibrotic activity, and produced no treatment-related serious adverse events in the 35-subject study.
GRI Bio, Inc. reported topline Phase 2a data for its oral drug candidate GRI-0621 in idiopathic pulmonary fibrosis, showing the trial met its primary endpoint of safety and tolerability over a 12-week treatment period. The company reports GRI-0621 was well tolerated with no treatment-related serious adverse events and adverse events mainly limited to grade 2 and grade 3 issues such as dry skin, dry lips, and musculoskeletal pain.
Placebo-adjusted changes in lung function, measured by Forced Vital Capacity, improved in patients receiving GRI-0621 alone and in combination with standard of care, and a higher share of treated patients experienced FVC increases compared with placebo. Serum biomarkers of multiple collagen types suggested an anti-fibrotic effect and potential activation of alveolar basement membrane repair, which are important for lung tissue recovery. The randomized, double-blind trial enrolled 35 IPF patients, most on background pirfenidone or nintedanib, and secondary and exploratory biomarker and pharmacodynamic analyses are ongoing.